Express Pharma

Sun Pharma announces settlement of patent litigation for generic Linzess in US

3

The Companies will grant, the wholly owned subsidiaries of Sun Pharma, a license to market a generic version of Linzess beginning February 1, 2031

Sun Pharmaceutical Industries including its subsidiaries and/ or associate companies recently announced that its wholly owned subsidiaries have reached an agreement with Ironwood Pharmaceuticals and Allergan plc (together known as “the Companies”) to resolve the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Linzess (Linaclotide capsules) in the US.

Pursuant to the terms of the settlement, the Companies will grant, the wholly owned subsidiaries of Sun Pharma, a license to market a generic version of Linzess in the US beginning February 1, 2031 (subject to USFDA approval) or earlier under certain circumstances. As a result of the settlement, all Hatch-Waxman litigation between Sun Pharma and the Companies, regarding the Linzess patents, will be dismissed. Additional details regarding the settlement were not disclosed. The agreement is subject to customary regulatory approvals.

Comments are closed.